338 related articles for article (PubMed ID: 32992737)
21. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
22. Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers.
Song L; Yang Y; Tian X
Cancer Drug Resist; 2024; 7():17. PubMed ID: 38835341
[TBL] [Abstract][Full Text] [Related]
23. Predictive factors for immunotherapy in melanoma.
Teixidó C; González-Cao M; Karachaliou N; Rosell R
Ann Transl Med; 2015 Sep; 3(15):208. PubMed ID: 26488004
[TBL] [Abstract][Full Text] [Related]
24. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music M; Prassas I; Diamandis EP
Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
[TBL] [Abstract][Full Text] [Related]
25. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients.
Jensen C; Madsen DH; Hansen M; Schmidt H; Svane IM; Karsdal MA; Willumsen N
J Immunother Cancer; 2018 Dec; 6(1):152. PubMed ID: 30567561
[TBL] [Abstract][Full Text] [Related]
26. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint inhibitors: therapeutic advances in melanoma.
Márquez-Rodas I; Cerezuela P; Soria A; Berrocal A; Riso A; González-Cao M; Martín-Algarra S
Ann Transl Med; 2015 Oct; 3(18):267. PubMed ID: 26605313
[TBL] [Abstract][Full Text] [Related]
28. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
29. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
30. Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.
Frankel AE; Coughlin LA; Kim J; Froehlich TW; Xie Y; Frenkel EP; Koh AY
Neoplasia; 2017 Oct; 19(10):848-855. PubMed ID: 28923537
[TBL] [Abstract][Full Text] [Related]
31. Checkpoint inhibitor responses can be regulated by the gut microbiota - A systematic review.
Zeriouh M; Raskov H; Kvich L; Gögenur I; Bennedsen ALB
Neoplasia; 2023 Sep; 43():100923. PubMed ID: 37603952
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of resistance to immune checkpoint inhibitors.
Jenkins RW; Barbie DA; Flaherty KT
Br J Cancer; 2018 Jan; 118(1):9-16. PubMed ID: 29319049
[TBL] [Abstract][Full Text] [Related]
33. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
34. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
Qian JM; Yu JB; Kluger HM; Chiang VL
Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
[TBL] [Abstract][Full Text] [Related]
35. Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy.
Strudel M; Festino L; Vanella V; Beretta M; Marincola FM; Ascierto PA
Curr Med Chem; 2020; 27(17):2792-2813. PubMed ID: 31804158
[TBL] [Abstract][Full Text] [Related]
36. A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma.
Hu J; Liu B; Hu W; Yang Y
Heliyon; 2022 Dec; 8(12):e12648. PubMed ID: 36619423
[TBL] [Abstract][Full Text] [Related]
37. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
Okuyama R
Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
[TBL] [Abstract][Full Text] [Related]
38. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
Loo K; Daud AI
Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
[TBL] [Abstract][Full Text] [Related]
39. Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates.
Seyhan AA; Carini C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613491
[TBL] [Abstract][Full Text] [Related]
40. [Development of immune checkpoint inhibitors].
Kitano S
Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]